Mavacamten: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted mavacamten, while AOTMIT (Poland) did not recommend it.
The record spans 3.2 years, opening at PBAC (Australia) in 2022 and running to 27 Oct 2025.
CIPM (Spain) changed its position: not recommended on 17 Jul 2024, recommended by 26 Sep 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 16 of 17 records date from 2023 or later.
4 distinct indication wordings are recorded for mavacamten by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 17 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess mavacamten, in 2022; AIFA (Italy) did not open a file until 27 Oct 2025 — a wide spread of 3.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 17 dated records fall in 2024 alone.
3 of the 13 agencies here assessed mavacamten more than once, PBAC (Australia) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
mavacamten has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for mavacamten reads 10 recommended, 4 not recommended, 1 no benefit and 1 deferred, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CHUIKYO (Japan) | 21 May 2025 | カムザイオスカプセル１ｍｇ | listed on the NHI price list · 55 days after PMDA approval | source |
| CIPM (Spain) | 17 Jul 2024 | Indicación terapéutica autorizada: CAMZYOS está indicado para el tratamiento de la miocardiopatía hipertrófica obstructi… | not financed by the SNS (financed 2024-09) | source |
| HIRA (South Korea) | 13 Jun 2024 | 증상성 폐색성 비대성 심근병증 | deferred for re-review | source |
| ZIN (Netherlands) | 1 May 2024 | Advies - vergoed mavacamten (Camzyos®) voor de behandeling van een bepaalde hartspierziekte | reimbursed | source |
| SMC (Scotland) | 8 Apr 2024 | For treatment of symptomatic (New York Heart Association, NYHA, class II III) obstructive hypertrophic cardiomyopathy (HOCM) in adult patients. | accepted | source |
12 further decisions for mavacamten, across 10 agencies, are not shown here. They include the most recent record on file, 27 Oct 2025 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 10 further source documents.
Related molecules
- ivabradine — same ATC class C01E — Cardiac therapy
- ranolazine — same ATC class C01E — Cardiac therapy
- acoramidis — same ATC class C01E — Cardiac therapy
- alprostadil — same ATC class C01E — Cardiac therapy
- regadenoson — same ATC class C01E — Cardiac therapy
- retifanlimab — also decided by AIFA in 2025Q4
Coverage: 17 decisions for mavacamten from 13 agencies, 2022 to 2025. Data to 7 Sep 2026. ATC class C01E — Cardiac therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.